GlassScriptPhysician profile
Anjali Bhandarkar
NPI 1700879954
$3,538.66
in general payments reported to CMS, 2019-2025
34 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $172 · 2021: $58.15 · 2022: $222 · 2023: $228 · 2024: $855 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $582.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $342.00 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.65 | 2019-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $214.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $211.49 | 2019-2025 | |
| Lilly USA, LLC | $206.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $198.58 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $185.24 | 2022-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $114.50 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $113.22 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $106.05 | 2019-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $92.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $89.98 | 2019-2025 | Verquvo |
| Abbott Laboratories | $86.20 | 2019-2024 | Freestyle Libre 3 |
| Abbvie INC. | $82.60 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $65.31 | 2025 | Uptravi, Opsumit, Opsynvi |
| Astellas Pharma US INC | $64.06 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $55.89 | 2019-2022 | |
| Amarin Pharma, INC. | $55.65 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.15 | 2024-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $41.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.23 | 2019 | |
| Phathom Pharmaceuticals, INC. | $36.19 | 2025 | Voquezna |
| Scilex Pharmaceuticals INC. | $30.15 | 2019 | |
| Hologic Sales and Service, LLC | $20.93 | 2025 | Aptima, Thinprep 2000 Processor |
| Biocomposites INC | $20.25 | 2024 | |
| Phadia US INC. | $19.24 | 2025 | Immunocap |
| Genentech USA, INC. | $18.98 | 2019 | |
| Acadia Pharmaceuticals INC | $16.69 | 2024 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $16.14 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $14.69 | 2025 | Rexulti |
| Allergan, INC. | $12.08 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.25 | 2019 | |
| Impulse Dynamics (USA) INC. | $10.78 | 2025 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Bhandarkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.